NeuroBo Pharmaceuticals (NRBO) Competitors

NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Greenidge Generation (NASDAQ:GREE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.

Does the MarketBeat Community believe in NRBO or GREE?

NeuroBo Pharmaceuticals received 18 more outperform votes than Greenidge Generation when rated by MarketBeat users. Likewise, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 33.33% of users gave Greenidge Generation an outperform vote.

Company	Underperform	Outperform
NeuroBo Pharmaceuticals	Outperform Votes 27 75.00%	Underperform Votes 9 25.00%
Greenidge Generation	Outperform Votes 9 33.33%	Underperform Votes 18 66.67%

Do institutionals & insiders have more ownership in NRBO or GREE?

1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. Comparatively, 8.5% of Greenidge Generation shares are held by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are held by company insiders. Comparatively, 27.8% of Greenidge Generation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts rate NRBO or GREE?

Greenidge Generation has a consensus price target of $4.00, suggesting a potential upside of 170.87%. Given Greenidge Generation's stronger consensus rating and higher probable upside, analysts plainly believe Greenidge Generation is more favorable than NeuroBo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroBo Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Greenidge Generation	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is NRBO or GREE more profitable?

NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Greenidge Generation's net margin of -20.09%. Greenidge Generation's return on equity of 0.00% beat NeuroBo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroBo Pharmaceuticals	N/A	-189.12%	-122.31%
Greenidge Generation	-20.09%	N/A	-18.76%

Which has higher earnings & valuation, NRBO or GREE?

NeuroBo Pharmaceuticals has higher earnings, but lower revenue than Greenidge Generation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47M	N/A	N/A
Greenidge Generation	$59.44M	0.38	-$29.51M	N/A	N/A

Does the media favor NRBO or GREE?

In the previous week, Greenidge Generation had 1 more articles in the media than NeuroBo Pharmaceuticals. MarketBeat recorded 2 mentions for Greenidge Generation and 1 mentions for NeuroBo Pharmaceuticals. NeuroBo Pharmaceuticals' average media sentiment score of 0.75 beat Greenidge Generation's score of 0.04 indicating that NeuroBo Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroBo Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenidge Generation	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has more volatility and risk, NRBO or GREE?

NeuroBo Pharmaceuticals has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, Greenidge Generation has a beta of 3.18, suggesting that its stock price is 218% more volatile than the S&P 500.

Summary

Greenidge Generation beats NeuroBo Pharmaceuticals on 10 of the 15 factors compared between the two stocks.